The m/m trials did not break out deaths. M/m w
Post# of 145351
M/m without expectation of death.
Also 84 patients rather than 10s of thousands with convalescent plasma.
64% fewer SAES in the leronlimab group (which if we "did a Hahn" and noted that none of the SAEs were attributed to Leronlimab by the investigators), would be a 100% reduction.
![Like This Post](/images/thumb-up.png)
![Dislike This Post](/images/thumb-down.png)